Impact of Repeated Doses of Subcutaneous Esketamine on Acute Dissociative Symptoms in Treatment-Resistant Depression.

Lorena Catarina Del SantLuciana Maria SarinAna Cecília LuccheseEduardo Jorge Muniz MagalhãesMarco Aurélio TuenaCarolina NakahiraJosé Alberto Del PortoAcioly Luiz Tavares Lacerda Jair de Jesus Mari

Published in: Pharmaceuticals (Basel, Switzerland) (2022)

Our results suggest that repeated subcutaneous esketamine doses are safe and well-tolerated regarding their acute dissociative and psychotomimetic symptoms. Symptoms usually peak at 30 min and decrease at 60 min post-injection, returning to their pretreatment levels at 120 min. Dissociative symptoms do not correlate with antidepressant response.

Keyphrases

sleep quality
liver failure
respiratory failure
depressive symptoms
drug induced
physical activity
hepatitis b virus
ultrasound guided